A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Top Cited Papers
- 30 September 2012
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 18 (10), 1570-1574
- https://doi.org/10.1038/nm.2942
Abstract
Hemophilia A is a bleeding disorder resulting from coagulation factor VIII (FVIII) deficiency. Exogenously provided FVIII effectively reduces bleeding complications in patients with severe hemophilia A. In approximately 30% of such patients, however, the 'foreignness' of the FVIII molecule causes them to develop inhibitory antibodies against FVIII (inhibitors), precluding FVIII treatment in this set of patients1,2,3. Moreover, the poor pharmacokinetics of FVIII, attributed to low subcutaneous bioavailability and a short half-life of 0.5 d, necessitates frequent intravenous injections3,4,5. To overcome these drawbacks, we generated a humanized bispecific antibody to factor IXa (FIXa) and factor X (FX), termed hBS23, that places these two factors into spatially appropriate positions and mimics the cofactor function of FVIII. hBS23 exerted coagulation activity in FVIII-deficient plasma, even in the presence of inhibitors, and showed in vivo hemostatic activity in a nonhuman primate model of acquired hemophilia A. Notably, hBS23 had high subcutaneous bioavailability and a 2-week half-life and would not be expected to elicit the development of FVIII-specific inhibitory antibodies, as its molecular structure, and hence antigenicity, differs from that of FVIII. A long-acting, subcutaneously injectable agent that is unaffected by the presence of inhibitors could markedly reduce the burden of care for the treatment of hemophilia A.This publication has 48 references indexed in Scilit:
- A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic ControlDiabetes, 2012
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS projectHaemophilia, 2011
- Immunogenicity of protein therapeutics: The key causes, consequences and challengesSelf/Nonself, 2010
- Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor SignalingPublished by Elsevier BV ,2010
- Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting miceProceedings of the National Academy of Sciences of the United States of America, 2008
- The tertiary structure and domain organization of coagulation factor VIIIBlood, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Contrasting IgG Structures Reveal Extreme Asymmetry and FlexibilityJournal of Molecular Biology, 2002
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986